A detailed history of China Universal Asset Management Co., Ltd. transactions in 89bio, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 20,370 shares of ETNB stock, worth $179,663. This represents 0.02% of its overall portfolio holdings.

Number of Shares
20,370
Previous 11,560 76.21%
Holding current value
$179,663
Previous $92,000 63.04%
% of portfolio
0.02%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$7.36 - $9.66 $64,841 - $85,104
8,810 Added 76.21%
20,370 $150,000
Q2 2024

Jul 19, 2024

SELL
$7.31 - $10.9 $46,345 - $69,106
-6,340 Reduced 35.42%
11,560 $92,000
Q1 2024

Apr 29, 2024

BUY
$8.13 - $13.77 $74,413 - $126,036
9,153 Added 104.64%
17,900 $208,000
Q4 2023

May 21, 2024

SELL
$6.66 - $16.03 $60,958 - $146,722
-9,153 Reduced 51.13%
8,747 $97,000
Q4 2023

Jan 23, 2024

BUY
$6.66 - $16.03 $45,301 - $109,036
6,802 Added 349.72%
8,747 $98,000
Q3 2023

May 21, 2024

BUY
$15.06 - $19.41 $14,909 - $19,215
990 Added 103.66%
1,945 $30,000
Q3 2023

Oct 30, 2023

BUY
$15.06 - $19.41 $14,909 - $19,215
990 Added 103.66%
1,945 $30,000
Q2 2023

May 21, 2024

BUY
$14.15 - $22.03 $3,820 - $5,948
270 Added 39.42%
955 $18,000
Q2 2023

Jul 27, 2023

BUY
$14.15 - $22.03 $3,820 - $5,948
270 Added 39.42%
955 $18,000
Q1 2023

May 21, 2024

BUY
$10.48 - $16.94 $2,221 - $3,591
212 Added 44.82%
685 $10,000
Q1 2023

Apr 27, 2023

BUY
$10.48 - $16.94 $2,221 - $3,591
212 Added 44.82%
685 $10,000
Q4 2022

May 21, 2024

SELL
$5.52 - $12.73 $96,197 - $221,845
-17,427 Reduced 97.36%
473 $6,000
Q4 2022

Jan 31, 2023

BUY
$5.52 - $12.73 $590 - $1,362
107 Added 29.23%
473 $6,000
Q3 2022

Oct 21, 2022

BUY
$3.02 - $7.0 $1,105 - $2,562
366 New
366 $2,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $410M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.